Five Pipeline Developments to Watch in 2023

From biosimilars and COVID-19 to gene therapy and microbiomes, there are several developments in the pipeline to watch...

Read More

Looking Ahead to 2023: Medicare Readiness

The 2022 audit cycle is coming to a close. CMS issued its last engagement letters for 2022 program audits at the end of...

Read More

New Guidelines for Diabetes First Line Therapy Could Lead to Increases in Drug Spend

Diabetes is an epidemic that drives a significant amount of medical cost. Eleven percent of the United States’...

Read More

Elixir’s 2023 Formularies Drive Optimal Value with Under 1% Member Disruption

At Elixir, whole member health is at the heart of our formulary strategy and drug management practices. As we prepare...

Read More

Taking the Limits Out of Limited Distribution Drugs for Specialty Medication Access

Specialty medications are not only used to treat complex conditions, they are themselves complex in nature. Some have...

Read More

Inflation Reduction Act of 2022: The Basics

On August 16th, 2022, President Biden signed into law H.R. 5376, a budget reconciliation measure known as the Inflation...

Read More

What to Know for the 2022-2023 Flu Season

According to the Centers for Disease Control and Prevention (CDC), there were as many as 14,000 flu-related deaths and...

Read More

Is it Worth the Download: Digital Therapeutics' Place in Healthcare

Digital therapeutics (DTx) uses software programs to prevent, manage or treat diseases. They may be used with or...

Read More

Biosimilars Versus Interchangeability: What You Need to Know

Specialty medications continue to be a large source of drug spend, in particular biologic drugs. Biosimilars pose an...

Read More

Demonstrating the Value of Specialty Medications that Treat Cystic Fibrosis

Cystic fibrosis (CF) is a rare genetic disorder that affects one in 3,900 live births. There are approximately 30,000...

Read More